Slate Medicines | $130,000,000 | (Feb 25, 2026)
Letter AI | $40,000,000 | (Feb 25, 2026)
Subject | $28,000,000 | (Feb 25, 2026)
Certified by Founder
Lodge
Orakl Oncology
start up
France
- Paris, Île-de-France
- 04/10/2023
- Unknown
- $3,147,000
Orakl leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.
- Industry Biotechnology Research
- Website https://www.orakl-oncology.com/
- LinkedIn https://www.linkedin.com/company/orakloncology/about/
Related People
Fanny JaulinFounder
France -
Greater Paris Metropolitan Region
My research goals are two-fold: to study the biology of live primary cancer specimens to build relevant knowledge and to implement cell biology approaches in the clinic to patient benefits.
To serve these ambitious objectives, my lab develops cell biology expertise, organoid technology and leads collaborative multidisciplinary programs. Together, we articulate a continuum in biomedical research, from fundamental questions to clinical applications.
KrisAtWork | $3,000,000 | (Feb 25, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Slang AI | $36,000,000 | (Feb 25, 2026)
Brilliant Harvest Inc. | $4,000,000 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)
General Magic | $7,200,000 | (Feb 25, 2026)
Circadian Risk Inc. | $6,000,000 | (Feb 25, 2026)
Neural Earth | $9,300,000 | (Feb 25, 2026)
Jampack AI | $3,200,000 | (Feb 25, 2026)